INT313868

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.41
First Reported 2010
Last Reported 2010
Negated 1
Speculated 0
Reported most in Body
Documents 2
Total Number 6
Disease Relevance 0.67
Pain Relevance 0.08

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

oxidoreductase activity (Pah)
Anatomy Link Frequency
lymphocyte 1
heart 1
Pah (Mus musculus)
Pain Link Frequency Relevance Heat
Calcium channel 2 98.44 Very High Very High Very High
beta blocker 1 61.44 Quite High
cytokine 5 5.00 Very Low Very Low Very Low
fluoxetine 5 5.00 Very Low Very Low Very Low
Inflammatory response 5 5.00 Very Low Very Low Very Low
antidepressant 5 5.00 Very Low Very Low Very Low
headache 3 5.00 Very Low Very Low Very Low
cva 2 5.00 Very Low Very Low Very Low
carbamazepine 1 5.00 Very Low Very Low Very Low
fibrosis 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Pulmonary Hypertension 66 100.00 Very High Very High Very High
Cv General 4 Under Development 22 91.40 High High
Birth Weight 35 90.40 High High
Nicotine Addiction 30 89.08 High High
Disease 17 70.40 Quite High
Heart Rate Under Development 1 64.48 Quite High
Hypertension 6 28.56 Quite Low
Dyslipidemia /

Combined Dyslipidemia

1 27.44 Quite Low
Obstructive Airway Disease 2 26.32 Quite Low
Dyspnea 3 6.48 Low Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Calcium channel blocker use should be restricted to patients with WHO FC I–III patients with idiopathic PAH who demonstrate a positive response to a vasodilator challenge at the time of right heart catheterization.
Positive_regulation (idiopathic) of PAH in heart associated with pulmonary hypertension and calcium channel
1) Confidence 0.41 Published 2010 Journal Drug design, development and therapy Section Body Doc Link PMC2880338 Disease Relevance 0.41 Pain Relevance 0.08
The percentage of CD19+ cells was lower in the first month, showed no significant association with exposures from months two through six, and increased from months seven through nine for total PAH exposure.
Neg (no) Positive_regulation (increased) of PAH
2) Confidence 0.21 Published 2010 Journal Environ Health Section Body Doc Link PMC2927516 Disease Relevance 0 Pain Relevance 0
For instance, a 100 ng/m3 incremental increase in PAH exposure during month eight was associated with reduction of CD3+ cells by 2.6% (95% CI: 1.2, 3.9) and CD4+ cells by 1.8% (95% CI: 0.6, 2.9).
Positive_regulation (increase) of PAH
3) Confidence 0.19 Published 2010 Journal Environ Health Section Body Doc Link PMC2927516 Disease Relevance 0 Pain Relevance 0
For gestational month one there was a 2.5% (95% confidence interval (CI): 0.9, 4.0) increase in CD3+ cells for 100 ng/m3 increment in PAH (Figure 1).
Positive_regulation (increase) of PAH
4) Confidence 0.18 Published 2010 Journal Environ Health Section Body Doc Link PMC2927516 Disease Relevance 0 Pain Relevance 0
For example, there was 1.4% (95% CI: 0.1, 2.7) decrease during month one and 1.2% (95% CI: 0.1, 2.4) increase during month eight for a 100 ng/m3 increase in PAH exposure (Figure 9).
Positive_regulation (increase) of PAH
5) Confidence 0.17 Published 2010 Journal Environ Health Section Body Doc Link PMC2927516 Disease Relevance 0 Pain Relevance 0
Results were expressed as changes in distribution of lymphocyte subtype with a monthly average increase of 100 ng/m3 PAH exposure or a monthly average increase of 25 ?
Positive_regulation (increase) of PAH in lymphocyte
6) Confidence 0.17 Published 2010 Journal Environ Health Section Body Doc Link PMC2927516 Disease Relevance 0.26 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox